BC Cancer Agency
Vancouver, British Columbia
An innovative approach to selectively target dormant leukemic stem cells
Despite encouraging advances in the treatment of leukemia, many blood cancers resist therapy or come back after initially responding. This is because the inability of current therapies to eradicate slow-growing blood cancer stem cells and their supporting cells in the bone marrow. This proposal aims to develop new combination therapies against other key proteins (ILK), so that these critical cells can be eliminated to improve survival in blood cancers.